Hypothyroidism is a condition in which the thyroid gland does not produce enough thyroid hormone, leading to slowed metabolic processes and multisystem symptoms such as fatigue, cold intolerance, weight gain, and cognitive slowing. It can be primary, central, congenital, or acquired. Treatment is typically thyroid hormone replacement.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.
Pembrolizumab-based regimens demonstrated significant survival improvements in two separate trials: KEYNOTE-B15 for muscle-invasive bladder cancer and KEYNOTE-B96 for platinum-resistant ovarian cancer, with FDA approval granted for the ovarian cancer indication.
Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.
The FDA approved pembrolizumab in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥1).
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07793279 |
Hypothyroidism and Liver Fibrosis Severity in MASLD |
NOT_YET_RECRUITING | |
| NCT07787585 |
Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism |
NOT_YET_RECRUITING | PHASE4 |
| NCT07781514 |
Vitamin E Add-On Therapy, Thyroid Function & Oxidative Stress in Levothyroxine-Treated Hypothyroidism |
ENROLLING_BY_INVITATION | NA |
| NCT07747103 |
An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets. |
RECRUITING | PHASE3 |
| NCT07733375 |
Evaluation of Levothyroxine Replacement Therapy After Total Thyroidectomy Using a Smart Wristband |
RECRUITING | |
| NCT07707830 |
Internal Organ and Musculoskeletal Assessment in Hypothyroidism (HYPOMORPH) |
RECRUITING | |
| NCT07688824 |
The Effect of SPU on Hormonal and Cardiometabolic Factors |
COMPLETED | NA |
| NCT07636681 |
Effect of Medication Adherence-Based Digital Intervention on Fatigue Severity, Weight, and Thyroid Hormone Regulation |
NOT_YET_RECRUITING | NA |
| NCT07616570 |
Serum Adipokines and Metabolic Parameters With Hormone Replacement in Newly Diagnosed Hypothyroidism |
COMPLETED | |
| NCT07421869 |
SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial |
RECRUITING | NA |
